Repligen Co. (NASDAQ:RGEN) – Analysts at William Blair reduced their Q1 2018 earnings estimates for shares of Repligen in a note issued to investors on Tuesday. William Blair analyst A. Murphy now expects that the biotechnology company will earn $0.14 per share for the quarter, down from their previous estimate of $0.16. William Blair also issued estimates for Repligen’s Q3 2018 earnings at $0.16 EPS, Q4 2018 earnings at $0.20 EPS, FY2018 earnings at $0.70 EPS and FY2019 earnings at $0.83 EPS.
Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.12 by $0.08. Repligen had a return on equity of 7.08% and a net margin of 20.08%. The business had revenue of $41.60 million for the quarter, compared to the consensus estimate of $41.13 million. During the same period last year, the business posted $0.08 EPS. The business’s revenue was up 62.5% compared to the same quarter last year.
Repligen (NASDAQ RGEN) opened at $36.03 on Wednesday. Repligen has a fifty-two week low of $29.56 and a fifty-two week high of $46.81. The stock has a market capitalization of $1,613.21, a price-to-earnings ratio of 52.87, a PEG ratio of 2.49 and a beta of 0.94. The company has a debt-to-equity ratio of 0.17, a current ratio of 9.63 and a quick ratio of 8.08.
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. grew its stake in Repligen by 1.6% during the 4th quarter. BlackRock Inc. now owns 5,360,343 shares of the biotechnology company’s stock worth $194,473,000 after buying an additional 81,858 shares during the last quarter. TimesSquare Capital Management LLC grew its stake in Repligen by 8.5% during the 4th quarter. TimesSquare Capital Management LLC now owns 2,511,120 shares of the biotechnology company’s stock worth $91,103,000 after buying an additional 196,900 shares during the last quarter. William Blair Investment Management LLC grew its stake in Repligen by 70.1% during the 4th quarter. William Blair Investment Management LLC now owns 1,802,569 shares of the biotechnology company’s stock worth $65,397,000 after buying an additional 742,634 shares during the last quarter. Conestoga Capital Advisors LLC grew its stake in Repligen by 14.9% during the 4th quarter. Conestoga Capital Advisors LLC now owns 1,669,562 shares of the biotechnology company’s stock worth $60,572,000 after buying an additional 216,330 shares during the last quarter. Finally, Mackenzie Financial Corp grew its stake in Repligen by 585.1% during the 4th quarter. Mackenzie Financial Corp now owns 940,066 shares of the biotechnology company’s stock worth $34,106,000 after buying an additional 802,848 shares during the last quarter. Hedge funds and other institutional investors own 87.60% of the company’s stock.
In related news, CEO Anthony Hunt sold 8,970 shares of the business’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $35.95, for a total transaction of $322,471.50. Following the transaction, the chief executive officer now directly owns 83,613 shares in the company, valued at approximately $3,005,887.35. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Howard Benjamin sold 12,729 shares of the business’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $35.34, for a total value of $449,842.86. Following the transaction, the vice president now owns 36,554 shares in the company, valued at $1,291,818.36. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 26,395 shares of company stock worth $942,122. 1.50% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/03/14/william-blair-weighs-in-on-repligen-co-s-q1-2018-earnings-rgen.html.
Repligen Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.